文献速递炎症性肠病

接受免疫抑制治疗的炎症性肠病患者中耶氏肺孢子菌肺炎感染风险低

Low Risk of Pneumonia From Pneumocystis jirovecii Infection in Patients With Inflammatory Bowel Disease Receiving Immune Suppression.
PubMed 文献 · Clin Gastroenterol Hepatol · 2016-12-21

该研究基于美国明尼苏达州奥姆斯特德县人群队列,纳入1970年至2011年确诊的937例炎症性肠病(IBD)患者,随访至2016年2月,评估使用糖皮质激素、免疫抑制剂和生物制剂时耶氏肺孢子菌肺炎(PJP)的风险。结果显示仅3例PJP,各暴露组风险均低,作者认为常规PJP预防可能不必要,但高危组如三联治疗者应考虑预防。

要点

  • 937例IBD患者随访6066患者年,仅3例耶氏肺孢子菌肺炎。
  • 糖皮质激素暴露555.4患者年,PJP风险0.2例/100患者年(95%CI 0.01-1.0)。
  • 作者认为常规PJP预防可能不必要,但高危组如三联治疗者应考虑预防。

核心结论

  • 在接受糖皮质激素、免疫抑制剂和生物制剂治疗的IBD人群队列中,尽管PJP预防使用不普遍,仅发生3例PJP,常规PJP预防可能不必要,但高危组如接受三联治疗者应考虑预防。

研究设计与样本

  • 基于人群的队列研究,纳入美国明尼苏达州奥姆斯特德县1970年至2011年确诊的克罗恩病427例和溃疡性结肠炎510例,共937例,随访至2016年2月,中位随访14.8年/患者。

主要发现

  • 糖皮质激素暴露520例(55.5%),555.4患者年,PJP风险0.2例/100患者年(95%CI 0.01-1.0)。
  • 免疫抑制剂暴露304例(32.4%),1555.7患者年,PJP风险0.1例/100患者年(95%CI 0.02-0.5)。
  • 生物制剂暴露193例(20.5%),670患者年,PJP风险0.3例/100患者年(95%CI 0.04-1.1)。
  • 双联治疗(糖皮质激素联合免疫抑制剂或生物制剂)236例(25.2%),173患者年,PJP风险0.6例/100患者年(95%CI 0.01-3.2)。
  • 三联治疗(糖皮质激素、免疫抑制剂和生物制剂)70例(7.5%),18.9患者年,PJP风险0例/100患者年(95%CI 0.0-19.5)。

关键数值与推荐

  • 共3例PJP,37例患者接受PJP一级预防,总暴露24.9患者年。

临床怎么用

  • 作者认为在这些患者中常规给予PJP预防可能不必要,但高危组如接受三联治疗者应考虑预防。

局限性

  • 原文未报告局限性

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND & AIMS: Use of immunosuppressants and inflammatory bowel disease (IBD) may increase the risk of pneumonia caused by Pneumocystis jirovecii (PJP). We assessed the risk of PJP in a population-based cohort of patients with IBD treated with corticosteroids, immune-suppressive medications, and biologics. METHODS: We performed a population-based cohort study of residents of Olmsted County, Minnesota, diagnosed with Crohn's disease (n = 427) or ulcerative colitis (n = 510) from 1970 through 2011. Records of patients were reviewed to identify all episodes of immunosuppressive therapies and concomitant PJP prophylaxis through February 2016. We reviewed charts to identify cases of PJP, cross-referenced with the Rochester Epidemiology Project database (using diagnostic codes for PJP) and the Mayo Clinic and Olmsted Medical Center databases. The primary outcome was risk of PJP associated with the use of corticosteroids, immune-suppressive medications, and biologics by patients with IBD. RESULTS: Our analysis included 937 patients and 6066 patient-years of follow-up evaluation (median, 14.8 y per patient). Medications used included corticosteroids (520 patients; 55.5%; 555.4 patient-years of exposure), immunosuppressants (304 patients; 32.4%; 1555.7 patient-years of exposure), and biologics (193 patients; 20.5%; 670 patient-years of exposure). Double therapy (corticosteroids and either immunosuppressants and biologics) was used by 236 patients (25.2%), with 173 patient-years of exposure. Triple therapy (corticosteroids, immunosuppressants, and biologics) was used by 70 patients (7.5%) with 18.9 patient-years of exposure. There were 3 cases of PJP, conferring a risk of 0.2 (95% CI, 0.01-1.0) to corticosteroids, 0.1 (95% CI, 0.02-0.5) cases per 100 patient-years of exposure to immunosuppressants, 0.3 (95% CI, 0.04-1.1) cases per 100 patient-years of exposure to biologics, 0.6 (95% CI, 0.01-3.2) cases per 100 patient-years of exposure to double therapy, and 0 (95% CI, 0.0-19.5) cases per 100 patient-years of exposure to triple therapy. Primary prophylaxis for PJP was prescribed to 37 patients, for a total of 24.9 patient-years of exposure. CONCLUSIONS: In a population-based cohort of patients with IBD treated with corticosteroids, immunosuppressants, and biologics, there were only 3 cases of PJP, despite the uncommon use of PJP prophylaxis. Routine administration of PJP prophylaxis in these patients may not be warranted, although it should be considered for high-risk groups, such as patients receiving triple therapy.

来源:Clin Gastroenterol Hepatol,查看原文。版权归原作者所有。

引用

  1. Cotter TG, Gathaiya N, Catania J, et al. Low Risk of Pneumonia From Pneumocystis jirovecii Infection in Patients With Inflammatory Bowel Disease Receiving Immune Suppression. Clin Gastroenterol Hepatol. 2016. PMID: 28013116. doi:10.1016/j.cgh.2016.11.037

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。